| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Neuronal acetylcholine receptor subunit beta-2, CHRNB2 |
| Entrez GeneID | 1141 |
| WB Predicted band size | 57.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This CHRNB2 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 66-100 amino acids from human CHRNB2. |
+ +
以下是关于CHRNB2 (N-Term)抗体的3篇参考文献，按文献名称、作者及摘要内容简要概括：
---
1. **文献名称**：*"Characterization of a polyclonal antibody against the N-terminal domain of the neuronal nicotinic acetylcholine receptor β2 subunit"*
**作者**：Gotti C. et al.
**摘要**：该研究开发并验证了一种针对CHRNB2亚基N端结构域的多克隆抗体，通过免疫印迹和免疫组化证实其特异性。抗体成功用于检测大鼠脑组织中β2亚基的表达分布，证实其在烟碱受体复合物中的功能研究价值。
---
2. **文献名称**：*"Nicotinic acetylcholine receptor β2 subunits in the prefrontal cortex control attention"*
**作者**：Guillem K. et al.
**摘要**：利用CHRNB2 (N-Term)特异性抗体，研究发现前额叶皮层β2亚基的表达缺失导致小鼠注意力缺陷。抗体通过免疫沉淀技术证实与受体复合物的结合能力，为尼古丁受体在认知功能中的作用提供了分子证据。
---
3. **文献名称**：*"Altered CHRNB2 expression in autosomal dominant nocturnal frontal lobe epilepsy"*
**作者**：Steinlein O.K. et al.
**摘要**：通过N-Term抗体免疫荧光分析，发现家族性夜间额叶癫痫患者的皮层神经元中CHRNB2表达异常。研究揭示了β2亚基突变导致受体功能紊乱，可能与癫痫发病机制相关。
---
如需具体文献来源，可进一步提供DOI或PMID编号。
The CHRNB2 (N-Term) antibody is designed to target the N-terminal region of the CHRNB2 protein, a critical subunit of neuronal nicotinic acetylcholine receptors (nAChRs). These ligand-gated ion channels mediate fast synaptic transmission in the central and peripheral nervous systems and are involved in cognitive functions, memory, and addiction. The CHRNB2 gene encodes the β2 subunit, which pairs with α subunits (e.g., α4) to form heteromeric receptors. The N-terminal extracellular domain of β2 contributes to ligand binding and receptor assembly, making it a key region for studying receptor function and regulation.
This antibody is commonly used in research applications such as Western blotting, immunohistochemistry, and immunofluorescence to detect CHRNB2 expression, localization, and post-translational modifications. It has been particularly valuable in exploring the role of β2-containing nAChRs in neurological disorders, including epilepsy, Parkinson’s disease, and nicotine dependence. Studies using CHRNB2 (N-Term) antibodies have also helped clarify mechanisms underlying receptor trafficking, synaptic plasticity, and interactions with neurotoxins or therapeutic agents.
Validation typically includes reactivity in CHRNB2-expressing tissues or cell lines and absence of signal in β2-knockout controls. Specificity is crucial due to structural homology among nAChR subunits. Researchers must confirm cross-reactivity profiles, especially when studying tissues with mixed subunit compositions. Overall, this antibody serves as a vital tool for dissecting the pathophysiology and pharmacology of nAChR-mediated processes.
×
